出典: meddic


tissue plasminogen activator
tissue plasminogen activator/t-PA

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/12/27 06:59:52」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.


  • Nilotinib Does Not Alter the Secretory Functions of Carotid Artery Endothelial Cells in a Prothrombotic or Antithrombotic Fashion.
  • Katgı A1, Sevindik ÖG2, Gökbulut AA3, Özsan GH1, Yüksel F1, Solmaz ŞM1, Alacacıoğlu İ1, Özcan MA1, Demirkan F1, Baran Y3, Pişkin Ö1.
  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.Clin Appl Thromb Hemost.2015 Oct;21(7):678-83. doi: 10.1177/1076029614550817. Epub 2014 Sep 18.
  • BACKGROUND: There have been concerns about the possible prothrombotic effects of nilotinib, especially in patients having cardiovascular risk factors. The potential mechanism behind the increased risk of thromboembolic events is still not clear.OBJECTIVES: In this study, we aimed to evaluate possibl
  • PMID 25239946
  • Stroke: Advances in Medical Therapy and Acute Stroke Intervention.
  • Barrett KM1, Lal BK, Meschia JF.
  • Current cardiology reports.Curr Cardiol Rep.2015 Oct;17(10):637. doi: 10.1007/s11886-015-0637-1.
  • Evidence-based therapeutic options for stroke continue to emerge based on results from well-designed clinical studies. Ischemic stroke far exceeds hemorrhagic stroke in terms of prevalence and incidence, both in the USA and worldwide. The public health effect of reducing death and disability related
  • PMID 26277364
  • Changing Contraindications for t-PA in Acute Stroke: Review of 20 Years Since NINDS.
  • Parker S1, Ali Y.
  • Current cardiology reports.Curr Cardiol Rep.2015 Oct;17(10):633. doi: 10.1007/s11886-015-0633-5.
  • When intravenous (IV) tissue-type plasminogen activator (t-PA) was originally approved by the Food and Drug Administration (FDA) for acute ischemic stroke (AIS) in 1996, there was a lengthy list of contraindications. In the 19 years since the approval of t-PA for AIS, it has been used off label and
  • PMID 26277361


  • ダビガトラン内服中に出血合併症なく血栓溶解療法を施行しえた心原性脳塞栓症の1例 : 症例報告と文献的考察
  • 稲石 淳,野川 茂,眞野 恵範 [他]
  • 臨床神経学 = Clinical neurology 54(3), 238-240, 2014-03
  • NAID 40020006671
  • ダビガトラン内服中に出血合併症なく血栓溶解療法を施行しえた心原性脳塞栓症の1例―症例報告と文献的考察
  • 稲石 淳,野川 茂,眞野 恵範,吉崎 崇仁,岡田 聡
  • 臨床神経学 54(3), 238-240, 2014
  • 症例は72歳男性である.心不全で入院し,心房細動をみとめたためダビガトラン220 mg/日が開始された.第3病日ダビガトラン内服4.5時間後に左不全麻痺,構音障害が出現した.APTT(activated partial thromboplastin time) 39.1秒,NIHSS(NIH Stroke Scale)11点で,発症160分後,ダビガトラン内服7時間後にrt-PA(recombin …
  • NAID 130004505575
  • 当院における救急遠隔診療支援システム(k-support)30例の解析 (JTTA 2013 TAKAMATSU 第17回日本遠隔医療学会学術大会 : 遠隔医療による国際協力と日本版EHRの確立を目指して) -- (地域医療連携(2))
  • 小幡 史明,田畑 良,影治 照喜
  • 日本遠隔医療学会雑誌 9(2), 214-217, 2013-10
  • NAID 40019824356


Before using alteplase: Some medical conditions may interact with alteplase. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you: if you are pregnant, planning to become ...
Learn more about Activase® (Alteplase) for Acute Ischemic Stroke Treatment. Indications Activase (alteplase) is indicated for the treatment of acute ischemic stroke. Exclude intracranial hemorrhage as the primary cause of stroke ...



リンク元tissue plasminogen activator」「アルテプラーゼ

tissue plasminogen activator」

  [★] 組織プラスミノゲンアクチベータ, t-PA, tPA, plasmino gen activators, tissuetype

alteplase、Alteplase, Retavase



組織プラスミノゲンアクチベーター t-PA